Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Extension in Pediatric ITP
NCT02201290Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Started Jun 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02201290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201290.